A 34-year-old woman, Serological screening results at 18 gestational weeks indicated a low risk (risk value: 1:3900). Doctors recommend non-invasive prenatal testing (NIPT) in view of the advanced maternal age. NIPT results showed that the fetus has a high risk of trisomy 21 which following confirmed by amniocentesis diagnosis of 47, XN, +21. Finally, this woman chose to terminate pregnancy to avoid giving birth to a sick baby.
B
A
S
E
C
A
R
E
Reagent/Prenatal
Noninvasive prenatal testing
The most advanced non-invasive screening technology for down syndrome, with the advantages of high accuracy and low risk of miscarriage, suitable for most ordinary people.
Product introduction
Noninvasive Prenatal Testing
There are more than 900,000 birth defects in China every year, and the total incidence of birth defects is about 5.6%, among which, Down's syndrome (trisomy 21), Edward's syndrome (trisomy 18) and patau's syndrome (trisomy 13) accounted for 80~90% of all birth defects. BaseNIPT is a prenatal screening designed to test the free fetal DNA in pregnant women’s peripheral blood and evaluate the risk of aneuploidy (Trisomy 21, Trisomy 18, Trisomy 13 etc.), the accuracy of this test is 99%.
Target group
Pregnant women concerned about the health of their fetuses
Pregnant women who don't want to do amniocentesis
Serological screening suggests a high risk of pregnancy
Serological screening high-risk pregnant women
Patients with interventional prenatal diagnosis contraindications
Pregnancy 20+6 weeks or more, missed the best time for serological screening
Advantages
Noninvasive
Only peripheral blood is needed, no risks for miscarriage
Fast
Test report will be issued within 20 working days
Accuracy
Comprehensive DNA testing, provide over 99% accuracy
Early detection
Test can be performed at 12 weeks gestational age
Insurance
Up to 400,000 yuan health insurance to protect patients interests
Cost-effective
Lower price benefit from upgraded technology
Service process
